Pubmed- Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results - IBD Reporter Newsfeed - IBD Support Group Forums - IBDsupport.org

Advertisement

Jump to content


Photo
- - - - -

Pubmed- Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results


  • Please log in to reply
No replies to this topic

#1 Health Reporter

Health Reporter

    Newsfeeder

  • RSS
  • PipPipPipPip
  • 20847 posts
  • Country:United States

Posted 14 September 2021 - 02:42 PM

Advertisement

Rev Esp Enferm Dig. 2021 Sep 14. doi: 10.17235/reed.2021.8320/2021. Online ahead of print.

ABSTRACT

A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. In an effort to limit patient attendance at intravenous infusion centers and to maintain biological treatment during the COVID-19 pandemic, the use of this new formulation was requested. The objective of this observational, retrospective, and descriptive study was to assess CT-P13 efficacy and safety after switching from intravenous to subcutaneous formulation in patients with IBD receiving maintenance therapy. This article shows preliminary results after six months of follow-up.

PMID:34517718 | DOI:10.17235/reed.2021.8320/2021

 

View the full article




Advertisement




© Copyright 1995-2014 IBD Support All rights reserved.

About Us | Contact Us | Advertise With Us | Disclaimer | Terms of Service | Crisis Resources

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information: verify here